Victor Sokolov
Victor Sokolov has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Kirill Peskov
Sechenov First Moscow State Medical University (Sechenov University)
7 shared publications - Alina Volkova
Marchuk Institute of Numerical Mathematics of the Russian Academy of Sciences (RAS), Moscow, Russia
4 shared publications - Robert Penland
Quantitative Clinical Pharmacology, Early Clinical Development, IMED Biotech Unit, AstraZeneca, Waltham, Massachusetts
4 shared publications - Tatiana Yakovleva
M&S Decisions Moscow Russia
4 shared publications - Weifeng Tang
Clinical Pharmacology & Quantitative Pharmacology Clinical Pharmacology and Safety Sciences R&D, AstraZeneca Gaithersburg Maryland USA
4 shared publications - Cristina Leon
M&S Decisions FZ LLC Dubai UAE
3 shared publications
Latest Publications
- Open Access
- 2 August 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (8) , e70307
Bayesian Workflow for Minimal PBPK Models: Case Study of Dapagliflozin
Numerous clinical trials (CTs) and population pharmacokinetic (PK) models have been published on dapagliflozin, an approved SGLT2 inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. This study proposes a Bayesian workflow for the development of minimal physiologically‐based PK models (mPBPK) that integrates all available PK information, to support uncertainty quantification and informed drug development. First, a systematic collection of published dapagliflozin PK data and models was performed. A mPBPK model was then developed, and posterior parameter distributions were obtained based on data from parallel‐design CTs. Three Bayesian modeling packages: NIMBLE (v1.1.0), MCSim (v6.2.0), and Torsten (v0.89.0), and three alternative prior specifications were evaluated. Model validation was performed using PK data from crossover CTs and urinary recovery data, followed by sensitivity analysis. 18 studies reporting PK data and 10 reporting PK models were identified. Posterior distributions were comparable across programs: 95% credible intervals overlapped. Torsten showed superior sampling efficiency, as compared to NIMBLE and MCSim (5.7 and 10.0 times higher in tails and central posterior regions, respectively); however, the average effective sample size per hour was comparable for Torsten and MCSim . The predicted urinary recovery was 2.2%–4.4% (mean 3.2%), while the observed values were in the 0.8%–4.0% range (mean 2.0%). Glomerular filtration rate and fraction unbound were the main contributors to inter‐trial variability in urinary recovery, while volume of distribution and clearance had the highest influence on maximum concentration and area‐under‐the‐concentration curve, respectively. The proposed Bayesian workflow is flexible and transferable to other mechanistic model types.
- 2 August 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (8) , e70307
Open AccessBayesian Workflow for Minimal PBPK Models: Case Study of Dapagliflozin
Numerous clinical trials (CTs) and population pharmacokinetic (PK) models have been published on dapagliflozin, an approved SGLT2 inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. This study proposes a Bayesian workflow for the development of minimal physiologically‐based PK models (mPBPK) that integrates all available PK information, to support uncertainty quantification and informed drug development. First, a systematic collection of published dapagliflozin PK data and models was performed. A mPBPK model was then developed, and posterior parameter distributions were obtained based on data from parallel‐design CTs. Three Bayesian modeling packages: NIMBLE (v1.1.0), MCSim (v6.2.0), and Torsten (v0.89.0), and three alternative prior specifications were evaluated. Model validation was performed using PK data from crossover CTs and urinary recovery data, followed by sensitivity analysis. 18 studies reporting PK data and 10 reporting PK models were identified. Posterior distributions were comparable across programs: 95% credible intervals overlapped. Torsten showed superior sampling efficiency, as compared to NIMBLE and MCSim (5.7 and 10.0 times higher in tails and central posterior regions, respectively); however, the average effective sample size per hour was comparable for Torsten and MCSim . The predicted urinary recovery was 2.2%–4.4% (mean 3.2%), while the observed values were in the 0.8%–4.0% range (mean 2.0%). Glomerular filtration rate and fraction unbound were the main contributors to inter‐trial variability in urinary recovery, while volume of distribution and clearance had the highest influence on maximum concentration and area‐under‐the‐concentration curve, respectively. The proposed Bayesian workflow is flexible and transferable to other mechanistic model types.
- 19 May 2026
- Published by The R Foundation
SimuRg: Building, Fitting and Evaluating PK/PD Modeles
Provides a unified workflow for building, fitting using external engines, and evaluating ordinary differential equation (ODE)-based pharmacokinetic/pharmacodynamic (PK/PD) models. Supports generation of estimation scenarios and control files for external engines (e.g., 'Monolix'), simulation of models using 'rxode2', and creation of goodness-of-fit diagnostics. Includes tools for covariate modeling, virtual population design, and local and global sensitivity analyses.
- 19 May 2026
- Published by The R Foundation
SimuRg: Building, Fitting and Evaluating PK/PD Modeles
Provides a unified workflow for building, fitting using external engines, and evaluating ordinary differential equation (ODE)-based pharmacokinetic/pharmacodynamic (PK/PD) models. Supports generation of estimation scenarios and control files for external engines (e.g., 'Monolix'), simulation of models using 'rxode2', and creation of goodness-of-fit diagnostics. Includes tools for covariate modeling, virtual population design, and local and global sensitivity analyses.
- Open Access
- 19 June 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (4) , 853-864
Exposure‐Response Relationships for Axatilimab in Patients with Chronic Graft‐Versus‐Host Disease
Axatilimab, a high‐affinity humanized monoclonal antibody that targets colony‐stimulating factor 1 receptor, is approved for the treatment of chronic graft‐versus‐host disease (cGVHD). Here, we describe the exposure‐response relationships for efficacy and safety in patients with cGVHD who received axatilimab. Exposure‐efficacy relationships were assessed in treated patients in the AGAVE‐201 study (n = 239); exposure‐safety relationships were assessed in treated patients in AGAVE‐201 (n = 239) and the phase 1/2 SNDX‐6352‐0503 study (n = 39). For binary or time‐to‐event endpoints, logistic or Cox regression analyses, respectively, were performed using axatilimab exposure metrics that were derived from a previously developed population pharmacokinetic/pharmacodynamic model. Overall response and ≥ 7‐point improvement in modified Lee Symptom Scale responses were associated with axatilimab exposure, with lower axatilimab exposure increasing the odds of a response. Duration of response was not associated with axatilimab exposure. Ten of 11 safety endpoints were associated with axatilimab exposure, with higher axatilimab exposure increasing the odds of adverse events. Among the 3 regimens evaluated in AGAVE‐201, the 0.3 mg/kg once every 2 weeks (Q2W) regimen had the highest predicted probability of response. Additionally, this dose group had the lowest predicted probability of event occurrence across all 10 safety endpoints associated with exposure among the evaluated regimens. Despite body weight influencing axatilimab exposure by > 20%, its effect on efficacy and safety endpoints remained minimal, with a maximum difference of ≤ 0.4% and ≤ 4.4% between the 1st and 4th quartiles of body weight, respectively. Taken together, these findings support the benefit–risk profile of axatilimab 0.3 mg/kg Q2W in patients with cGVHD.
- 19 June 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (4) , 853-864
Open AccessExposure‐Response Relationships for Axatilimab in Patients with Chronic Graft‐Versus‐Host Disease
Axatilimab, a high‐affinity humanized monoclonal antibody that targets colony‐stimulating factor 1 receptor, is approved for the treatment of chronic graft‐versus‐host disease (cGVHD). Here, we describe the exposure‐response relationships for efficacy and safety in patients with cGVHD who received axatilimab. Exposure‐efficacy relationships were assessed in treated patients in the AGAVE‐201 study (n = 239); exposure‐safety relationships were assessed in treated patients in AGAVE‐201 (n = 239) and the phase 1/2 SNDX‐6352‐0503 study (n = 39). For binary or time‐to‐event endpoints, logistic or Cox regression analyses, respectively, were performed using axatilimab exposure metrics that were derived from a previously developed population pharmacokinetic/pharmacodynamic model. Overall response and ≥ 7‐point improvement in modified Lee Symptom Scale responses were associated with axatilimab exposure, with lower axatilimab exposure increasing the odds of a response. Duration of response was not associated with axatilimab exposure. Ten of 11 safety endpoints were associated with axatilimab exposure, with higher axatilimab exposure increasing the odds of adverse events. Among the 3 regimens evaluated in AGAVE‐201, the 0.3 mg/kg once every 2 weeks (Q2W) regimen had the highest predicted probability of response. Additionally, this dose group had the lowest predicted probability of event occurrence across all 10 safety endpoints associated with exposure among the evaluated regimens. Despite body weight influencing axatilimab exposure by > 20%, its effect on efficacy and safety endpoints remained minimal, with a maximum difference of ≤ 0.4% and ≤ 4.4% between the 1st and 4th quartiles of body weight, respectively. Taken together, these findings support the benefit–risk profile of axatilimab 0.3 mg/kg Q2W in patients with cGVHD.
- Open Access
- 13 May 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (7) , 1225-1235
An Integrative Mechanistic Model of Type 1 IFN‐Mediated Inflammation in Systemic Lupus Erythematosus
Type I interferon (IFN1) pathway–targeting therapies represent a highly promising class of remedies for the treatment of systemic lupus erythematosus. However, the overall clinical benefit of these compounds is afflicted by marked variability. In this study, we developed a quantitative systems pharmacology model of type I IFN‐mediated inflammation and applied it for an indirect comparison of anifrolumab, sifalimumab, daxdilimab, and litifilimab pharmacodynamic response, represented in the model by the change in IFN1 gene signature (IFNGS). The model consists of 20 ordinary differential equations and 68 parameters, among which four systemic parameters (including one random effect) were estimated using patient‐level data from Phase IIb anifrolumab clinical trial. Within‐target and within‐pathway validation was performed using study‐level pharmacokinetics, IFNα, and/or IFNGS data from five anifrolumab, four sifalimumab, one daxdilimab, and one litifilimab trials. The model successfully captured overall trends in IFNGS at clinically relevant doses of these compounds and discriminated IFNGS response between patients with low (< 2.75) and high (≥ 2.75) baseline IFNGS. Overprediction of treatment benefit was observed for the low range of anifrolumab doses (100–150 mg every 4 weeks). In contrast, IFNGS response under 150 mg of daxdilimab was underpredicted, despite the accurate description of plasmacytoid dendritic cells and IFNα biomarkers. Results of the global sensitivity analysis revealed baseline IFNGS, IFNα, and IFNα fraction as key factors affecting treatment benefit the most. In terms of maximum IFNGS reduction, anifrolumab showed superior potential compared to sifalimumab, daxdilimab, and litifilimab (ΔIFNGS~25%), which was further enhanced in patients with high baseline IFNGS or IFNα (ΔIFNGS~50%–60%).
- 13 May 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (7) , 1225-1235
Open AccessAn Integrative Mechanistic Model of Type 1 IFN‐Mediated Inflammation in Systemic Lupus Erythematosus
Type I interferon (IFN1) pathway–targeting therapies represent a highly promising class of remedies for the treatment of systemic lupus erythematosus. However, the overall clinical benefit of these compounds is afflicted by marked variability. In this study, we developed a quantitative systems pharmacology model of type I IFN‐mediated inflammation and applied it for an indirect comparison of anifrolumab, sifalimumab, daxdilimab, and litifilimab pharmacodynamic response, represented in the model by the change in IFN1 gene signature (IFNGS). The model consists of 20 ordinary differential equations and 68 parameters, among which four systemic parameters (including one random effect) were estimated using patient‐level data from Phase IIb anifrolumab clinical trial. Within‐target and within‐pathway validation was performed using study‐level pharmacokinetics, IFNα, and/or IFNGS data from five anifrolumab, four sifalimumab, one daxdilimab, and one litifilimab trials. The model successfully captured overall trends in IFNGS at clinically relevant doses of these compounds and discriminated IFNGS response between patients with low (< 2.75) and high (≥ 2.75) baseline IFNGS. Overprediction of treatment benefit was observed for the low range of anifrolumab doses (100–150 mg every 4 weeks). In contrast, IFNGS response under 150 mg of daxdilimab was underpredicted, despite the accurate description of plasmacytoid dendritic cells and IFNα biomarkers. Results of the global sensitivity analysis revealed baseline IFNGS, IFNα, and IFNα fraction as key factors affecting treatment benefit the most. In terms of maximum IFNGS reduction, anifrolumab showed superior potential compared to sifalimumab, daxdilimab, and litifilimab (ΔIFNGS~25%), which was further enhanced in patients with high baseline IFNGS or IFNα (ΔIFNGS~50%–60%).
- 21 March 2025
- Published by Springer Nature
- p. 75-120
A Framework for Quantitative Systems Pharmacology Model Execution
A mathematical model can be defined as a theoretical approximation of an observed pattern. The specific form of the model and the associated mathematical methods are typically dictated by the question(s) to be addressed by the model and the underlying data. In the context of research and development of new medicines, these questions often focus on the dose-exposure-response relationship. The general workflow for model development and application can be delineated in three major elements: defining the model, qualifying the model, and performing simulations. These elements may vary significantly depending on modeling objectives. Quantitative systems pharmacology (QSP) models address the formidable challenge of quantitatively and mechanistically characterizing human and animal biology, pathophysiology, and therapeutic intervention. QSP model development, by necessity, relies heavily on preexisting knowledge, requires a comprehensive understanding of current physiological concepts, and often makes use of heterogeneous and aggregated datasets from multiple sources. This reliance on diverse datasets presents an upfront challenge: the determination of an optimal model structure while balancing model complexity and uncertainty. Additionally, QSP model calibration is arduous due to data scarcity (particularly at the human subject level), which necessitates the use of a variety of parameter estimation approaches and sensitivity analyses, earlier in the modeling workflow as compared to, for example, population modeling. Finally, the interpretation of model-based predictions must be thoughtfully aligned with the data and the mathematical methods applied during model development. The purpose of this chapter is to provide readers with a high-level yet comprehensive overview of a QSP modeling workflow, with an emphasis on the various challenges encountered in this process. The workflow is centered around the construction of ordinary differential equation models and may be extended beyond this framework. It includes the fundamentals of systematic literature reviews, the selection of appropriate structural model equations, the analysis of system behavior, model qualification, and the application of various types of model-based simulations. The chapter concludes with details on existing software options suitable for implementing the described methodologies. This workflow may serve as a valuable resource to both newcomers and experienced QSP modelers, offering an introduction to the field as well as operating procedures and references for routine analyses.
- 21 March 2025
- Published by Springer Nature
- p. 75-120
A Framework for Quantitative Systems Pharmacology Model Execution
A mathematical model can be defined as a theoretical approximation of an observed pattern. The specific form of the model and the associated mathematical methods are typically dictated by the question(s) to be addressed by the model and the underlying data. In the context of research and development of new medicines, these questions often focus on the dose-exposure-response relationship. The general workflow for model development and application can be delineated in three major elements: defining the model, qualifying the model, and performing simulations. These elements may vary significantly depending on modeling objectives. Quantitative systems pharmacology (QSP) models address the formidable challenge of quantitatively and mechanistically characterizing human and animal biology, pathophysiology, and therapeutic intervention. QSP model development, by necessity, relies heavily on preexisting knowledge, requires a comprehensive understanding of current physiological concepts, and often makes use of heterogeneous and aggregated datasets from multiple sources. This reliance on diverse datasets presents an upfront challenge: the determination of an optimal model structure while balancing model complexity and uncertainty. Additionally, QSP model calibration is arduous due to data scarcity (particularly at the human subject level), which necessitates the use of a variety of parameter estimation approaches and sensitivity analyses, earlier in the modeling workflow as compared to, for example, population modeling. Finally, the interpretation of model-based predictions must be thoughtfully aligned with the data and the mathematical methods applied during model development. The purpose of this chapter is to provide readers with a high-level yet comprehensive overview of a QSP modeling workflow, with an emphasis on the various challenges encountered in this process. The workflow is centered around the construction of ordinary differential equation models and may be extended beyond this framework. It includes the fundamentals of systematic literature reviews, the selection of appropriate structural model equations, the analysis of system behavior, model qualification, and the application of various types of model-based simulations. The chapter concludes with details on existing software options suitable for implementing the described methodologies. This workflow may serve as a valuable resource to both newcomers and experienced QSP modelers, offering an introduction to the field as well as operating procedures and references for routine analyses.
- Open Access
- 20 December 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (3) , 704-715
Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft‐Versus‐Host Disease
Axatilimab, a high‐affinity humanized immunoglobulin G4 monoclonal antibody against colony‐stimulating factor 1 receptor (CSF‐1R), is approved for the treatment of chronic graft‐versus‐host disease (cGVHD), and under investigation for idiopathic pulmonary fibrosis and solid tumors. The population pharmacokinetics (PK) and pharmacodynamics (PD) of axatilimab were characterized in healthy participants and patients with solid tumors or cGVHD using data from four clinical studies with 325 participants, including 278 patients with cGVHD. The model structure reflected the mechanism of action of axatilimab: blocking CSF‐1R signaling with axatilimab reduces the circulating levels of cells in the mononuclear phagocytic cell lineage (including nonclassical monocytic cells (NCMCs) and Kupffer cells), resulting in increases in circulating enzymes owing to reduced clearance by Kupffer cells. The structural model consisted of a two‐compartment axatilimab PK model and turnover PD models for CSF‐1, NCMCs, aspartate transaminase (AST), and creatine phosphokinase (CPK). Axatilimab PK and CSF‐1 equations also included saturable clearance components to reflect the competitive binding of axatilimab and CSF‐1 to CSF‐1R. Covariate search was conducted with the conditional sampling use for the stepwise approach based on correlation tests (COSSAC) approach. Covariate effects on model parameters, steady‐state axatilimab exposure, and NCMC concentrations were assessed. The final population PK/PD model was mathematically described with 6 ordinary differential equations and 39 model parameters. Among the 11 statistically significant covariates, one (body weight) and two (participant population type and baseline CPK) covariates affected axatilimab steady‐state exposure and steady‐state NCMC levels by > 20%, respectively. These results informed the axatilimab dosing strategy in patients with cGVHD.
- 20 December 2024
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 117 (3) , 704-715
Open AccessSemimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft‐Versus‐Host Disease
Axatilimab, a high‐affinity humanized immunoglobulin G4 monoclonal antibody against colony‐stimulating factor 1 receptor (CSF‐1R), is approved for the treatment of chronic graft‐versus‐host disease (cGVHD), and under investigation for idiopathic pulmonary fibrosis and solid tumors. The population pharmacokinetics (PK) and pharmacodynamics (PD) of axatilimab were characterized in healthy participants and patients with solid tumors or cGVHD using data from four clinical studies with 325 participants, including 278 patients with cGVHD. The model structure reflected the mechanism of action of axatilimab: blocking CSF‐1R signaling with axatilimab reduces the circulating levels of cells in the mononuclear phagocytic cell lineage (including nonclassical monocytic cells (NCMCs) and Kupffer cells), resulting in increases in circulating enzymes owing to reduced clearance by Kupffer cells. The structural model consisted of a two‐compartment axatilimab PK model and turnover PD models for CSF‐1, NCMCs, aspartate transaminase (AST), and creatine phosphokinase (CPK). Axatilimab PK and CSF‐1 equations also included saturable clearance components to reflect the competitive binding of axatilimab and CSF‐1 to CSF‐1R. Covariate search was conducted with the conditional sampling use for the stepwise approach based on correlation tests (COSSAC) approach. Covariate effects on model parameters, steady‐state axatilimab exposure, and NCMC concentrations were assessed. The final population PK/PD model was mathematically described with 6 ordinary differential equations and 39 model parameters. Among the 11 statistically significant covariates, one (body weight) and two (participant population type and baseline CPK) covariates affected axatilimab steady‐state exposure and steady‐state NCMC levels by > 20%, respectively. These results informed the axatilimab dosing strategy in patients with cGVHD.
- Open Access
- 23 November 2023
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (1) , 5-22
A tutorial for model‐based evaluation and translation of cardiovascular safety in preclinical trials
Assessment of drug‐induced effects on the cardiovascular (CV) system remains a critical component of the drug discovery process enabling refinement of the therapeutic index. Predicting potential drug‐related unintended CV effects in the preclinical stage is necessary for first‐in‐human dose selection and preclusion of adverse CV effects in the clinical stage. According to the current guidelines for small molecules, nonclinical CV safety assessment conducted via telemetry analyses should be included in the safety pharmacology core battery studies. However, the manual for quantitative evaluation of the CV safety signals in animals is available only for electrocardiogram parameters (i.e., QT interval assessment), not for hemodynamic parameters (i.e., heart rate, blood pressure, etc.). Various model‐based approaches, including empirical pharmacokinetic‐toxicodynamic analyses and systems pharmacology modeling could be used in the framework of telemetry data evaluation. In this tutorial, we provide a comprehensive workflow for the analysis of nonclinical CV safety on hemodynamic parameters with a sequential approach, highlight the challenges associated with the data, and propose respective solutions, complemented with a reproducible example. The work is aimed at helping researchers conduct model‐based analyses of the CV safety in animals with subsequent translation of the effect to humans seamlessly and efficiently.
- 23 November 2023
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (1) , 5-22
Open AccessA tutorial for model‐based evaluation and translation of cardiovascular safety in preclinical trials
Assessment of drug‐induced effects on the cardiovascular (CV) system remains a critical component of the drug discovery process enabling refinement of the therapeutic index. Predicting potential drug‐related unintended CV effects in the preclinical stage is necessary for first‐in‐human dose selection and preclusion of adverse CV effects in the clinical stage. According to the current guidelines for small molecules, nonclinical CV safety assessment conducted via telemetry analyses should be included in the safety pharmacology core battery studies. However, the manual for quantitative evaluation of the CV safety signals in animals is available only for electrocardiogram parameters (i.e., QT interval assessment), not for hemodynamic parameters (i.e., heart rate, blood pressure, etc.). Various model‐based approaches, including empirical pharmacokinetic‐toxicodynamic analyses and systems pharmacology modeling could be used in the framework of telemetry data evaluation. In this tutorial, we provide a comprehensive workflow for the analysis of nonclinical CV safety on hemodynamic parameters with a sequential approach, highlight the challenges associated with the data, and propose respective solutions, complemented with a reproducible example. The work is aimed at helping researchers conduct model‐based analyses of the CV safety in animals with subsequent translation of the effect to humans seamlessly and efficiently.
- Open Access
- 25 October 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1229255
Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model
Introduction: Dapagliflozin-induced improvement of glycemic control in patients with inadequately controlled type 1 diabetes (T1D) is complicated by the delicate balance between blood glucose and exogenous insulin. In this work, we developed a semi-mechanistic population exposure-response model using pooled patient-level data to characterize the joint effect of dapagliflozin and insulin on average daily glucose concentrations and glycated hemoglobin (HbA1c) levels in patients with T1D.Methods: A non-linear mixed-effects model was developed in Monolix (Lixoft, France) and R software (R Project, www.r-project.org) using pooled patient-level data from phase 2 and phase 3 trials (NCT01498185, NCT02460978, NCT02268214).Results: Because of the apparent lack of association between bolus insulin dose and glucose concentrations measured by continuous glucose monitoring the model was able to capture the quantitative link between basal, but not bolus, insulin dose and plasma glucose. Even so, this association remained flat, with a 50% decrease in the basal insulin dose from pretreatment level, resulting in ∼5% increase in glucose exposure. Therefore, dapagliflozin efficacy was not significantly affected by the insulin dose adjustment, with 24-week HbA1c reduction on 10-mg dapagliflozin treatment changing from −0.5 [95% CI: −0.55, −0.45] to −0.42 [95%CI: −0.48, −0.36] after adjustment. At the same time, the analysis revealed ∼2-fold steeper slope of glucose-HbA1c relationship in dapagliflozin-treated patients vs. control group, suggesting the presence of additional dapagliflozin treatment–related benefits, not explained by the dapagliflozin-mediated ∼4% increase in plasma hemoglobin levels. Finally, the efficacy of 5 and 10-mg doses, represented by the mean HbA1c reduction at week 24 of dapagliflozin treatment, was shown to be notably greater than the 1- and 2.5-mg doses.Discussion: This research is an attempt to deconvolute and reconstruct dapagliflozin-HbA1c dose-response relationship in T1D by accounting for the drug’s action on both daily insulin dose and plasma glucose on a subject-level. While the model is able to adequately capture the observed data, it also revealed that the variability in CGM is poorly approximated by the variability in insulin dose alone. Furthermore, the slope of CGM/HbA1c relationship may differ depending on the population and treatment scenarios. As such, a deeper dive into the physiological mechanisms is required to better quantify the intricate network of glycemic response under dapagliflozin treatment.
- 25 October 2023
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1229255
Open AccessEffectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model
Introduction: Dapagliflozin-induced improvement of glycemic control in patients with inadequately controlled type 1 diabetes (T1D) is complicated by the delicate balance between blood glucose and exogenous insulin. In this work, we developed a semi-mechanistic population exposure-response model using pooled patient-level data to characterize the joint effect of dapagliflozin and insulin on average daily glucose concentrations and glycated hemoglobin (HbA1c) levels in patients with T1D.Methods: A non-linear mixed-effects model was developed in Monolix (Lixoft, France) and R software (R Project, www.r-project.org) using pooled patient-level data from phase 2 and phase 3 trials (NCT01498185, NCT02460978, NCT02268214).Results: Because of the apparent lack of association between bolus insulin dose and glucose concentrations measured by continuous glucose monitoring the model was able to capture the quantitative link between basal, but not bolus, insulin dose and plasma glucose. Even so, this association remained flat, with a 50% decrease in the basal insulin dose from pretreatment level, resulting in ∼5% increase in glucose exposure. Therefore, dapagliflozin efficacy was not significantly affected by the insulin dose adjustment, with 24-week HbA1c reduction on 10-mg dapagliflozin treatment changing from −0.5 [95% CI: −0.55, −0.45] to −0.42 [95%CI: −0.48, −0.36] after adjustment. At the same time, the analysis revealed ∼2-fold steeper slope of glucose-HbA1c relationship in dapagliflozin-treated patients vs. control group, suggesting the presence of additional dapagliflozin treatment–related benefits, not explained by the dapagliflozin-mediated ∼4% increase in plasma hemoglobin levels. Finally, the efficacy of 5 and 10-mg doses, represented by the mean HbA1c reduction at week 24 of dapagliflozin treatment, was shown to be notably greater than the 1- and 2.5-mg doses.Discussion: This research is an attempt to deconvolute and reconstruct dapagliflozin-HbA1c dose-response relationship in T1D by accounting for the drug’s action on both daily insulin dose and plasma glucose on a subject-level. While the model is able to adequately capture the observed data, it also revealed that the variability in CGM is poorly approximated by the variability in insulin dose alone. Furthermore, the slope of CGM/HbA1c relationship may differ depending on the population and treatment scenarios. As such, a deeper dive into the physiological mechanisms is required to better quantify the intricate network of glycemic response under dapagliflozin treatment.
- 11 September 2023
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 37 (1) , 77-84
Model-Based Assessment of the Reference Values of CAVI in Healthy Russian Population and Benchmarking With CAVI0
BACKGROUND: Cardio-ankle vascular index (CAVI) and its modified version (CAVI0) are promising non-invasive markers of arterial stiffness, extensively evaluated primarily in the Japanese population. In this work, we performed a model-based analysis of the association between different population characteristics and CAVI or CAVI0 values in healthy Russian subjects and propose a tool for calculating the range of reference values for both types of indices. METHODS: The analysis was based on the data from 742 healthy volunteers (mean age 30.4 years; 73.45% men) collected from a multicenter observational study. Basic statistical analysis [analysis of variance, Pearson’s correlation (r), significance tests] and multivariable linear regression were performed in R software (version 4.0.2). Tested covariates included age, sex, BMI, blood pressure, and heart rate (HR). RESULTS: No statistically significant difference between healthy men and women were observed for CAVI and CAVI0. In contrast, both indices were positively associated with age (r = 0.49 and r = 0.43, P < 0.001), however, with no clear distinction between subjects of 20–30 and 30–40 years old. Heart rate and blood pressure were also identified as statistically significant predictors following multiple linear regression modeling, but with marginal clinical significance. Finally, the algorithm for the calculation of the expected ranges of CAVI in healthy population was proposed, for a given age category, HR and pulse pressure (PP) values. CONCLUSIONS: We have evaluated the quantitative association between various population characteristics, CAVI, and CAVI0 values and established a method for estimating the subject-level reference CAVI and CAVI0 measurements.
- 11 September 2023
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 37 (1) , 77-84
Model-Based Assessment of the Reference Values of CAVI in Healthy Russian Population and Benchmarking With CAVI0
BACKGROUND: Cardio-ankle vascular index (CAVI) and its modified version (CAVI0) are promising non-invasive markers of arterial stiffness, extensively evaluated primarily in the Japanese population. In this work, we performed a model-based analysis of the association between different population characteristics and CAVI or CAVI0 values in healthy Russian subjects and propose a tool for calculating the range of reference values for both types of indices. METHODS: The analysis was based on the data from 742 healthy volunteers (mean age 30.4 years; 73.45% men) collected from a multicenter observational study. Basic statistical analysis [analysis of variance, Pearson’s correlation (r), significance tests] and multivariable linear regression were performed in R software (version 4.0.2). Tested covariates included age, sex, BMI, blood pressure, and heart rate (HR). RESULTS: No statistically significant difference between healthy men and women were observed for CAVI and CAVI0. In contrast, both indices were positively associated with age (r = 0.49 and r = 0.43, P < 0.001), however, with no clear distinction between subjects of 20–30 and 30–40 years old. Heart rate and blood pressure were also identified as statistically significant predictors following multiple linear regression modeling, but with marginal clinical significance. Finally, the algorithm for the calculation of the expected ranges of CAVI in healthy population was proposed, for a given age category, HR and pulse pressure (PP) values. CONCLUSIONS: We have evaluated the quantitative association between various population characteristics, CAVI, and CAVI0 values and established a method for estimating the subject-level reference CAVI and CAVI0 measurements.
- Open Access
- 16 March 2023
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (6) , 831-841
A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes
Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by abnormally high blood glucose concentrations due to dysfunction of the insulin‐producing beta‐cells in the pancreas. Dapagliflozin, an inhibitor of renal glucose reabsorption, has the potential to improve often suboptimal glycemic control in patients with T1DM through insulin‐independent mechanisms and to partially mitigate the adverse effects associated with long‐term insulin administration. In this work, we have adapted a systems pharmacology model of type 2 diabetes mellitus to describe the T1DM condition and characterize the effect of dapagliflozin on short‐ and long‐term glycemic markers under various treatment scenarios. The developed platform serves as a quantitative tool for the in silico evaluation of the insulin‐glucose‐dapagliflozin crosstalk, optimization of the treatment regimens, and it can be further expanded to include additional therapies or other aspects of the disease.
- 16 March 2023
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 12 (6) , 831-841
Open AccessA mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes
Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by abnormally high blood glucose concentrations due to dysfunction of the insulin‐producing beta‐cells in the pancreas. Dapagliflozin, an inhibitor of renal glucose reabsorption, has the potential to improve often suboptimal glycemic control in patients with T1DM through insulin‐independent mechanisms and to partially mitigate the adverse effects associated with long‐term insulin administration. In this work, we have adapted a systems pharmacology model of type 2 diabetes mellitus to describe the T1DM condition and characterize the effect of dapagliflozin on short‐ and long‐term glycemic markers under various treatment scenarios. The developed platform serves as a quantitative tool for the in silico evaluation of the insulin‐glucose‐dapagliflozin crosstalk, optimization of the treatment regimens, and it can be further expanded to include additional therapies or other aspects of the disease.